CTL-DP 01NCT04180059
Phase I Study of CTL Anti-DP Infusion Post-hematopoietic Stem Cell Transplantation
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 12 versions: 10 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 15 words
- Primary completion date changed from estimate of Jul 2027 to Jul 8, 2026
- Study completion moved earlier from Aug 2027 to Dec 2026
- Study description expanded, about 2 words
- Notable Primary completion date: Apr 2025 to Jul 2027
- Study completion date: Apr 2026 to Aug 2027
- Minor Primary completion date: Feb 2025 to Apr 2025
- Study completion date: Feb 2027 to Apr 2026
- Notable Enrollment target: 20 to 6
- Study completion date: Sep 2025 to Feb 2027
- Study description expanded, about 145 words
- Notable Primary endpoint revised
- Secondary endpoints: details revised at 1 of 8 entries
Show 4 earlier versionsHide 4 earlier versions
- Notable Eligibility criteria expanded, about 2 wordsv6
- Notable Primary completion date: Sep 2022 to Feb 2025
- Enrollment target: 24 to 20
- Study completion date: Mar 2023 to Sep 2025
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Mar 2020 to Feb 9, 2020
- Site details revised
- Minor Study description shortened, about 2 wordsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
determine maximal tolerated dose of infusion of a third party suicide gene-transduced anti-HLA-DPB1*04:01 CD4+ T cell clone in HLA-DPB1*04:01 tumor positive recipients receiving an allo-HSCT from a HLA-DPB1*04:01 negative alternative donor.
Timeframe: 4 weeks after CTL injection
Secondary (8)
survival and persistence of the clone injected
immune reconstitution
incidence of relapse
survival
GVHD incidence
Show 3 moreShow less
mortality
complete remission
side effects of Clone
Arms and interventions
CTL 19 : T cell therapyExperimental
Level 1: 1 x 104 cells/kg of recipient, Level 2: 5 x 104 cells/kg, Level 3: 25 x 104 cells/kg, Level 4: 50 x 104 cells/kg, Level 5: 100 x 104 cells/kg. After study of toxicity of the 4 injected patients, choice has been made to stop the CRM method to choose the dose and to test only 2 doses for each last patients : 100 x 10\^4 cells/kg (actual level 5) and 500 x 10\^4 cells/kg (choice based on compassionnal injections data at the level 5)
Combination products: CTL 19
Sites
1 site in 1 country
- Chu de NantesNantes, France